Niagen Bioscience, Inc. (NAGE) Return on equity 2017–2025
Niagen Bioscience, Inc. (NAGE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
22.7%FY2025 · since FY2017: -21.1% → 22.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 22.7% | +4.2 pp |
| FY2024 | 18.5% | +35.9 pp |
| FY2023 | -17.4% | +40.3 pp |
| FY2022 | -57.7% | +27.8 pp |
| FY2021 | -85.5% | +35.8 pp |
| FY2020 | -121.3% | +35.9 pp |
| FY2019 | -157.2% | -34.7 pp |
| FY2018 | -122.6% | -101.4 pp |
| FY2017 | -21.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice